Circulating Tumor Cells (CTC), Prostate Cancer
The Circulating Tumor Cell (CTC) test provides a measurement of tumor (cancer) cells that are circulating in the bloodstream. It provides enumeration of circulating tumor cells (CTC) of epithelial origin in whole blood originating from tumors/cancers. The circulating tumor cells are epithelial in origin and are not normally found in blood and are extremely rare in individuals with no malignancy. Since tumor cells have a tendency to metastasize, blood would be one of the travel routes. Therefore, CTCs are mainly found in metastatic cancers. The CTC test measures the number of tumor cells that separated from the tumor and are circulating freely in the bloodstream. This assay uses specific markers to detect epithelial tumor cells in blood, and it is specific for epithelial cell tumor markers of prostate cancer origin. Therefore, this test is mainly utilized to determine and monitor the efficacy of treatment (such as chemotherapy) and prognosis of patients with metastatic cancer of the prostate. The results of this test are utilized to determine the efficacy of treatment (such as chemotherapy) and prognosis of patients with metastatic cancer of the prostate.
In prostate cancer, studies indicate that results of fewer than 5 CTCs has a mean survival rate of 2 ½ years. Subjects with > or = 5 CTCs had a median survival rate of about 11.5 months and any individual with more than 50 CTCs was predictive of shorter progression-free survival (PFS) and poorer overall survival (OS) for metastatic prostate cancer patients. The individuals with greater than 50 CTCs had a survival rate of approximately 6 months. It has been stated that the CTC test is a better predictor of active tumor metastasis than prostate-specific antigen (PSA). The reason for this is due to the fact that PSA is a measure of total tumor burden including the primary and any metastatic sites, while CTCs correlate with metastasizing tumors.
- Prostate cancer management
- Monitor response to treatment and overall survival rate
- If less than 5 CTCs are present in the blood of patient with prostate cancer, then survival rate of 2 ½ years is predicted. This suggests lymph node involvement only
- Subjects with between 5 and 50 CTCs indicates a survival rate of about 21 months
- Individual with more than 50 CTCs have shorter progression-free survival (PFS) and poorer overall survival (OS) for metastatic prostate cancer patients. Their survival rate is approximately 6 months
<5 CTC/7.5mL of whole blood (Negative for CTC)
10 mL room-temperature whole blood (CellSave Preservative Tube); 7.5 mL minimum volume. Ship promptly; specimen must be tested within 96 hours. Patient history pertinent to prostate cancer is required to perform this test.
- Mol Med. 2009 Mar–Apr; 15(3-4): 101–114. [PMID: 19081770]
- Ann Oncol. 2007 Mar;18(3):518-21. [PMID: 17322541]